A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2018
At a glance
- Drugs CS 1001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CStone Pharmaceuticals
- 21 Dec 2018 According to a CStone Pharmaceuticals media release, first three patients have been dosed.
- 19 Dec 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2018 Planned initiation date changed from 30 Nov 2018 to 30 Dec 2018.